To The Moon

Earnings Season is Here:

Yesterday's simulation returns were quite satisfactory: "Deutsche Bank Releases Space Data Outlook: How to Trade RKLB, PL, and LUNR After Their Surge?"

See the decent return in comment area please.

According to the earnings calendar shared by Tiger Brokers, after Wednesday's close, $Procter & Gamble(PG)$ , $Abbott Laboratories(ABT)$ , and $Freeport-McMoRan(FCX)$ will report earnings. Below are the key angles I'm focusing on and the options strategies I'm considering for discussion purposes only.

1. $Procter & Gamble(PG)$🔥 +1.71% Tuesday close: Pre-earnings breakout with volume, challenging the $148 resistance level?

Earnings Expectations: Institutions generally expect steady revenue and EPS growth. The company recently announced a strategic partnership with Casarte and continues brand marketing innovation, providing fundamental support.

Key Forward-Looking Points: Watch for organic sales growth maintained in the 3-5% range, gross margin improvement; FX negative impact of approximately 2-3%, easing raw material cost pressure; China market recovery progress, impact of pricing strategies on volume.

Current Valuation: Current P/E (TTM) at 21.46x is below its own forward P/E historical average of 23.86x, indicating reasonable valuation with a certain margin of safety.

Institutional Expectations: Among the 24 institutions covered by Tiger Brokers, the average price target is $165.23, representing approximately 12.4% upside from current levels. Rating distribution: 5 Strong Buy, 10 Buy, 12 Hold, indicating generally positive institutional sentiment.

Short-Term Price Expectations: PG stock likely to trade between $144.5-$148.0, awaiting earnings guidance.

• If earnings beat expectations and successfully break through the $148.02 resistance, short-term target moves up to the $152-$155 range.

• If earnings miss or break below the $144.52 support, may retest support in the $142-$140 region.

Three Options Strategies to Consider:

2. $Abbott Laboratories(ABT)$ -0.51% on Tuesday: Holding the $121 key pivot?

Earnings Expectations: Institutions expect 7.22% revenue growth and 11.49% EPS growth. The company has been active in medical devices recently, with its Atacor Medical subsidiary announcing a pivotal IDE clinical trial in 2026 for an innovative extravascular implantable cardioverter-defibrillator system, injecting new long-term growth prospects.

Key Forward-Looking Points: Stability of medical device demand, diagnostics business growth rate, nutrition business recovery (especially China), FX headwinds of 3-4%, GMP facility resolution progress.

Current Valuation: Current P/E (TTM) of 15.22x is below its own forward P/E historical average (~24.25x) and significantly below the medical device industry average.

Institutional Expectations: Among 31 institutions covered by Tiger Brokers, 9 Strong Buy and 12 Buy ratings. Average price target is $144.08, representing approximately 19% upside potential, with Barclays targeting as high as $169.

Short-Term Price Expectations: Stock likely to trade widely between $118-$126.

• If earnings beat and hold above $125.37 resistance, could test $130.

• If earnings miss and break below $120.25 support, could probe the $115 area.

Two Options Strategies to Consider:

3. $Freeport-McMoRan(FCX)$ +2.32% Tuesday: Gaining momentum pre-earnings, challenging historical high of $60.71 🔥

Earnings Expectations: Market expects >40% YoY EPS growth, focusing on cost control and production guidance. Goldman Sachs and Deutsche Bank reports emphasize copper market will remain structurally short due to supply bottlenecks and strong grid/AI demand, supporting mining stocks.

Key Forward-Looking Points: Copper price trends (China demand recovery key), Q4 production meeting guidance, unit cash cost changes, Indonesia operation permit progress, macro concerns vs. new energy long-term tailwinds, recent safety incidents properly handled with no casualties and limited operational impact.

Current Valuation: P/S (TTM) at 3.32x aligns with resource company valuation range. P/E (TTM) at 42.01x is significantly above industry average, reflecting market's premium for earnings growth during copper upcycle.

Institutional Viewpoints: 19 institutions covered by Tiger Brokers average price target $58.19, with high forecast of $69.0. Rating distribution: 4 Strong Buy, 14 Buy, 5 Hold, overall bullish sentiment.

Short-Term Price Expectations: Stock likely to trade between $58.35-$60.71 at elevated levels.

• If earnings beat and successfully break $60.71 resistance, next target range $62-$65.

• If earnings miss or broad market weakens, needs to retest support near $56.00.

Two Options Strategies to Consider:

On the eve of earnings, FCX is challenging its historical high of $60.71. Sufficient short-term momentum (strong RSI), mid-term uptrend (MACD golden cross). Expecting potential directional breakout post-earnings, but earnings themselves are a major uncertainty event.

Volatility Status: Implied Volatility (IV) at 47.31%, IV Percentile at 76.10%, IV/HV ratio at 1.31. This indicates options are very expensive, with market expecting massive post-earnings volatility.

⚠️ General Principles Reminders:

IV Crush: Post-earnings implied volatility typically drops 30-50%; avoid being a pure options buyer

• Position Sizing: Single position <5% of total portfolio

• Liquidity: Prioritize contracts with volume >1,000 to avoid inability to close

• Timing Concentration: Tuesday (INTC/ISRG) and Friday (FCX/GE) are crowded; watch Gamma risk

Disclaimer: The above analysis is for educational purposes only and does not constitute investment advice. Options trading carries extremely high risk and may result in total loss of principal. Please make decisions carefully based on your risk tolerance.